# Nabihah Tayob

List of Publications by Year
in descending order

| 45 papers | 2,362 citations | 430874
18
h-index | 265206
42
g-index |
|---|---|---|---|
| 45 all docs | 45 docs citations | 45 times ranked | 3611 citing authors |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1 | Risk of Pancreatic Cancer in Families With Lynch Syndrome. JAMA - Journal of the American Medical Association, 2009, 302, 1790. | 7.4 | 434 |
| 2 | Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteranâ€™s Affairs Health Care System. BMC Medical Research Methodology, 2018, 18, 1. | 3.1 | 390 |
| 3 | Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respiratory Medicine,the, 2014, 2, 548-556. | 10.7 | 353 |
| 4 | Predictors of Chronic Obstructive Pulmonary Disease Exacerbation Reduction in Response to Daily Azithromycin Therapy. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1503-1508. | 5.6 | 155 |
| 5 | Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function. Chest, 2014, 145, 579-585. | 0.8 | 95 |
| 6 | International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology, 2021, 160, 2572-2584. | 1.3 | 91 |
| 7 | Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. Journal of Clinical Oncology, 2021, 39, 1531-1539. | 1.6 | 88 |
| 8 | Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of Clinical Oncology, 2021, 39, 2375-2385. | 1.6 | 76 |
| 9 | Idiopathic Pulmonary Fibrosis. Chest, 2016, 149, 491-498. | 0.8 | 75 |
| 10 | GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology, 2022, 75, 541-549. | 7.3 | 70 |
| 11 | Improved Detection of Hepatocellular Carcinoma by Using aÂLongitudinal Alpha-Fetoprotein Screening Algorithm. Clinical Gastroenterology and Hepatology, 2016, 14, 469-475.e2. | 4.4 | 67 |
| 12 | The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. Clinical Gastroenterology and Hepatology, 2023, 21, 415-423.e4. | 4.4 | 56 |
| 13 | Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncology, 0, , . | 7.1 | 51 |
| 14 | Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clinical Gastroenterology and Hepatology, 2019, 17, 1886-1893.e5. | 4.4 | 36 |
| 15 | Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 1648-1655. | 0.8 | 33 |
| 16 | A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nature Communications, 2021, 12, 5574. | 12.8 | 32 |
| 17 | Spread of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal Province, South Africa. PLoS ONE, 2011, 6, e17513. | 2.5 | 29 |
| 18 | Association between Emphysema and Chronic Obstructive Pulmonary Disease Outcomes in the COPDGene and SPIROMICS Cohorts: A <i>Post Hoc</i> Analysis of Two Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 265-267. | 5.6 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research, 2021, 27, 983-991. | 7.0 | 29 |
| 20 | Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Research and Treatment, 2021, 189, 103-110. | 2.5 | 19 |
| 21 | A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. Npj Breast Cancer, 2022, 8, 63. | 5.2 | 18 |
| 22 | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. Npj Breast Cancer, 2021, 7, 103. | 5.2 | 17 |
| 23 | A Bayesian Screening Approach for Hepatocellular Carcinoma Using Multiple Longitudinal Biomarkers. Biometrics, 2018, 74, 249-259. | 1.4 | 16 |
| 24 | Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. Clinical Gastroenterology and Hepatology, 2021, 19, 1443-1450.e6. | 4.4 | 13 |
| 25 | Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Research and Treatment, 2021, 189, 203-212. | 2.5 | 11 |
| 26 | Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 113, 117-124. | 0.8 | 11 |
| 27 | Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18. | 5.2 | 8 |
| 28 | Nonparametric tests of treatment effect based on combined endpoints for mortality and recurrent events. Biostatistics, 2015, 16, 73-83. | 1.5 | 7 |
| 29 | Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Research and Treatment, 2021, 187, 843-852. | 2.5 | 7 |
| 30 | Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. JCO Precision Oncology, 2021, 5, 896-903. | 3.0 | 6 |
| 31 | Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecologic Oncology, 2021, 161, 581-586. | 1.4 | 5 |
| 32 | Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist, 2021, 26, 927-933. | 3.7 | 5 |
| 33 | A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecologic Oncology Reports, 2022, 40, 100974. | 0.6 | 5 |
| 34 | Unbiased Estimation of Biomarker Panel Performance When Combining Training and Testing Data in a Group Sequential Design. Biometrics, 2016, 72, 888-896. | 1.4 | 4 |
| 35 | Statistical consequences of a successful lung allocation system - recovering information and reducing bias in models for urgency. Statistics in Medicine, 2017, 36, 2435-2451. | 1.6 | 4 |
| 36 | DETECT: Development of Technologies for Early HCC Detection. Gastroenterology, 2022, 163, 21-27. | 1.3 | 4 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 37 | A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. Breast Cancer Research and Treatment, 2021, 189, 411-423. | 2.5 | 3 |
| 38 | Perceptions of patients with early stage breast cancer toward research biopsies. Cancer, 2021, 127, 1208-1219. | 4.1 | 3 |
| 39 | Nonparametric restricted mean analysis across multiple follow-up intervals. Statistics and Probability Letters, 2016, 109, 152-158. | 0.7 | 2 |
| 40 | Nonparametric group sequential methods for recurrent and terminal events from multiple follow‐up windows. Statistics in Medicine, 2019, 38, 5657-5669. | 1.6 | 2 |
| 41 | Nonparametric Group Sequential Methods for Evaluating Survival Benefit from Multiple Short-Term Follow-up Windows. Biometrics, 2019, 75, 494-505. | 1.4 | 1 |
| 42 | Regression analysis of recurrent‐event‐free time from multiple follow‐up windows. Statistics in Medicine, 2020, 39, 1-15. | 1.6 | 1 |
| 43 | A multivariate parametric empirical Bayes screening approach for early detection of hepatocellular carcinoma using multiple longitudinal biomarkers. Statistics in Medicine, 2022, 41, 2338-2353. | 1.6 | 1 |
| 44 | Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings. Breast Cancer Research and Treatment, 2022, 192, 201-210. | 2.5 | 0 |
| 45 | Personalized statistical learning algorithms to improve the early detection of cancer using longitudinal biomarkers. Cancer Biomarkers, 2022, 33, 199-210. | 1.7 | 0 |